论文部分内容阅读
Alemtuzumab是一种人源化单克隆抗体 ,对部分慢性淋巴细胞白血病 (CLL)的治疗效果非常好。本文回顾性分析了单独使用Alemtuzum ab治疗的CLL患者的细胞水平的变化 ,以确立早期预测病情缓解或复发的相关表现方法 本研究包括 43 (男 3 8、女 5)例 ,中位年龄 58(3 2～ 75)岁。所有
Alemtuzumab is a humanized monoclonal antibody that works well for some chronic lymphocytic leukemia (CLL). This paper retrospectively analyzed the cellular level changes of CLL patients treated with Alemtuzum ab alone to establish the relative performance of early prediction of disease remission or recurrence. This study included 43 (38 males and 5 females) patients with a median age of 58 3 2 ~ 75) years old. all